NEW YORK (Reuters Health) - Some patients with refractory vascular renal allograft rejection and accelerated hypertension have pathogenic antibodies directed at the angiotensin II type 1 (AT1) receptor, investigators report in the New England Journal of Medicine for February 10.
Your session will expire in 8 hours requiring you to log in each day to view content.
FEBRUARY 14, 2012